Qilin Zhang

7PUBLICATIONS
2CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Adolescent healthMolecular targetsInstrumental methods (excl. immunological and bioassay methods)Toxicology (incl. clinical toxicology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Mar 06, 2025
Cost-effectiveness of atezolizumab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in the US and Chinese setting: a modelling comparison study.

Lulu Liu, Lei Wang, Yiling Ding

|Feb 19, 2025
Cost-effectiveness analysis of a first-line treatment with cadonilimab plus platinum-based chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer in China: COMPASSION-16 trial.

Yiling Ding, Chunping Wang, Yamin Shu

|Aug 29, 2024
Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis.

Wenting Zhang, Ziqi Xu, Yamin Shu

|Jul 07, 2023
Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment.

Yamin Shu, Lei Wang, Yiling Ding

|Apr 10, 2023
Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system.

Yamin Shu, Yiling Ding, Lulu Liu

|Jul 24, 2022
Hematological toxicities in PARP inhibitors: A real-world study using FDA adverse event reporting system (FAERS) database.

Yamin Shu, Yufeng Ding, Xucheng He

Pageof 2

Frequent Collaborators

1 joint publications

Ziming Zheng

1 joint publications

Yu Zhang